地特胰岛素联合瑞格列奈治疗新诊断的2型糖尿病患者的有效性和安全性

目的评价地特胰岛素（Det）联合瑞格列奈治疗新诊断的2型糖尿病（T2DM）患者的有效性和安全性。方法将56例住院治疗的新诊断T2DM患者，随机分为Det联合瑞格列奈组和预混人胰岛素（诺和灵30R）组进行治疗，观察治疗前后的FBG、2hBG、HbA1c、低血糖发生率、体重增加情况和依从性。结果治疗12周后，两组患者的FBG、2hBG、HbA1c均较基线显著降低。Det联合瑞格列奈组和预混人胰岛素组，低血糖发生率分别为0．080、0．150，体重增加发生率分别为0．029、0．035，治疗依从率分别为0．893、0．679。结论Det联合瑞格列奈治疗，可显著降低新诊断的住院T2DM患者的血糖水平，并且具有较好的安全性和治疗依从性。

Therapeutic efficacy and safety of insulin detemir plus repaglinide in newly diagnosed type 2 diabetic inpatients

Objective To evaluate the efficacy and safety of insulin detemir combined with repaglinide in newly diagnosed type 2 diabetic inpatients. Methods All 56 T2DM inpatients newly diagnosed were divided randomly into two groups, one treated by insulin detemir combined with repaglinide, the other treated by premixed human insulin 30R. At baseline and the end of trial, FBG, 2hPG,HbA1c, glucose target arrival rate, hypoglycemia, weight gain and compliance were observed. Results After 12 weeks of treatment, levels of FBG, 2hBG- and HbA1c decreased significantly from baseline in both groups（P〈0. 05）, and the two groups got similar glucose control（P〉0. 05）. Compared with the premixed insulin group, insulin detemir combined with repaglinide group had lower hypoglycemia rate and less weight gain, and more patients wanted to continue this treatment protocol（all P〈0. 05）. Conclusions In newly diagnosed type 2 diabetic inpatients, insulin detemir combined with repaglinide treatment would improve glucose control significantly, and got better safety and treatment compliance.